Novartis to Buy Generic Drug Companies

APRIL 01, 2005

Novartis plans to expand its presence as a maker of generic drugs with the purchase of Hexal of Germany and its New York affiliate, Eon Labs, for a reported $8.4 billion in cash. Hexal is the second-largest generic drug manufacturer in Germany.

The purchase would give Novartis a much bigger piece of the generic drug pie. Hexal would bring Novartis >120 new products, including painkillers and cholesterol drugs. Eon would bring a low-cost copy of a popular antidepressant (bupropion) and an extensive pipeline of new generic drugs.

The acquisition will occur in stages. Novartis already has signed an agreement to pay $7.4 billion for all of Hexal and for 67.7% of Eon. After the transaction closes (scheduled for the second half of 2005), Novartis plans to offer $31 a share, or about $1 billion, for the rest of Eon.



SHARE THIS SHARE THIS
0
 

Conference Coverage

Check back here regularly for live conference coverage from the American Academy of Pain Medicine and the upcoming American Pharmacists Association Meeting and Expo. 


 

Pharmacy Times Strategic Alliance
 

Pharmacist Education
Clinical features with downloadable PDFs


Next-Generation Pharmacist® Awards


3rd Annual Convenient Healthcare and Pharmacy Collaborative Conference


SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.